Form 4: TransMedics Group Executive Tamer Khayal Exercises Options and Sells Shares
SEC Form 4 Filing
Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Tamer Khayal, Chief Commercial Officer of TransMedics Group, Inc., executed transactions involving the company's common stock on March 1, 2024.
- Khayal exercised options to purchase 10,000 shares of common stock at a price of $13.28 per share.
- Concurrently, Khayal sold 10,000 shares acquired from the option exercise and an additional 9,998 shares in multiple transactions at weighted average prices ranging from $81.49 to $85.18.
- These sales were conducted under a pre-arranged Rule 10b5-1 trading plan established on September 6, 2023.
- Following these transactions, Khayal directly owns 26,502 shares of common stock and indirectly owns 14,776 shares through the Khayal Family 2021 Irrevocable Trust and 11,051 shares through the Tamer Ibrahim Ahmed Khayal Trust.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of insider trading activity under a pre-arranged plan, which doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to sell shares over time, which helps avoid accusations of trading on inside information.
Comparison to Industry Standards
- Executive compensation packages often include stock options, and it's typical for executives to periodically exercise these options and sell shares for personal financial management.
- The use of a 10b5-1 trading plan is a standard practice to ensure compliance with insider trading regulations.
- Comparable companies in the medical device industry, such as Medtronic or Boston Scientific, also have executives who regularly report similar transactions.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- However, the pre-arranged nature of the sales mitigates concerns about insider information being used for personal gain.
Key Dates
| Date | Description |
|---|---|
| 2023-09-06 | Date of establishment of the Rule 10b5-1 trading plan |
| 2024-03-01 | Date of the transactions: option exercise and share sales |
| 2024-03-05 | Date of the Form 4 filing |
| 2026-02-22 | Date the option is fully vested |
| 2032-02-22 | Expiration date of the stock option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.